Clinical data | |
---|---|
Other names | PTI-125, PTI-910 |
ATC code |
|
Pharmacokinetic data | |
Elimination half-life | 4.5 hrs [1] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C15H21N3O |
Molar mass | 259.353 g·mol−1 |
3D model (JSmol) | |
| |
|
Simufilam (PTI-125) is an experimental medication for the treatment of Alzheimer's disease. [2] [3] It is being developed by the American pharmaceutical firm Cassava Sciences. The drug is in phase III clinical trials as of October 2023. There are two phase III clinical studies: RETHINK-ALZ, a 52-week trial, is set to complete in 2024, [4] and REFOCUS-ALZ, spanning 76 weeks, is projected to finish in 2025. [5]
The US Food and Drug Administration (FDA) received a citizen petition in August 2021 to stop the clinical trials and investigate simufilam. Other scientists have questioned the preclinical results, citing the small sample size, alleged methodological flaws in an in vitro technique, alleged manipulations of western blot images and potential conflict of interest. [6] [7] [8]
After the FDA said that the citizen petition was the improper procedure to request an investigation, Reuters reported in July 2022 that a criminal investigation of Cassava Sciences was started by the United States Department of Justice (DOJ) over research results related to the experimental drug. [9] The U.S. Securities and Exchange Commission (SEC), the U.S. National Institutes of Health (NIH), and City University of New York (CUNY) were also investigating whether Cassava or individuals manipulated data. [10] In June 2024, Wang was indicted by the United States Department of Justice (DOJ) for fraud and charged with falsifying data on $16 million in grant applications to the NIH related to simufilam. [11] [12] [13] [14]
From research funded by Cassava Sciences (then Pain Therapeutics), Lindsay Burns (Cassava's senior vice president of neuroscience), Hoau-Yan Wang (a CUNY professor and Cassava advisor), [10] and Maya Frankfurt (CUNY) reported in PLOS One the binding of a 300-kDa protein called filamin A (FLNA) with naloxone to prevent opioid tolerance and drug dependence. [15] The authors claimed this was a critical discovery of the binding of certain opioid antagonists (naloxone and naltrexone) to FLNA, a cytoskeletal protein that is critical in maintaining cell shape and division. [16] Burns and Wang reported the pentapeptide binding site on FLNA the next year. [17] Both of these papers were retracted by PLOS One in 2022. [6]
Wang separately identified a large protein associating with the alpha 7 nicotinic receptor when Abeta42 bound and signaled through this receptor in Alzheimer's disease models. He identified it as FLNA, and Wang and Burns tested the hypothesis that it was critical to the toxic signaling of soluble amyloid. In 2012, they stated in The Journal of Neuroscience that the compound PTI-125 disrupted FLNA linkage with the alpha 7 nicotinic receptor as well as the toxic signaling of Abeta42, presenting PTI-125 as a novel therapeutic strategy for Alzheimer's disease. [16] [18] The Journal of Neuroscience issued an expression of concern in 2022. [6]
Wang, Burns and co-authors reported in Neurobiology of Aging in 2017 showed that PTI-125 induced improvements in Alzheimer's disease pathology as it binds, and restores to normal, an altered conformation of FLNA in experimental Alzheimer's disease transgenic mice. [19] [20] Neurobiology of Aging issued an expression of concern for this paper in 2022. [6]
In 2018, the National Institutes of Health granted the company a research award for early clinical trials of PTI-125 as an Alzheimer's drug. [21] [22] In August 2020, the United States Adopted Names (USAN) assigned the drug chemical name as simufilam. [23]
Open-label studies started in March 2020, [6] and Cassava Sciences reported in May 2020 that initial biomarker analysis of cerebrospinal fluid (CSF) samples from its phase IIb clinical trials of PTI-125 had failed, but reported in September 2020 that a new analysis by an "outside lab" showed improvements in biomarkers, adding that individuals with Alzheimer's also showed improvements in cognition with simufilam. [6] [24] [25] It was later revealed that the outside lab was Wang's CUNY lab. [24] [6]
In October 2021, larger trials were initiated; [6] Cassava Sciences announced in December 2021 that the first phase III trial of simufilam would enroll about 750 participants, and the second 1,000. [6] [26] In the first quarter of 2022, 60 participants were enrolled; [6] Stat stated that enrollment had slowed as of April 2022, as people were deterred from enlisting due to the prevailing controversies. [27] In August 2022, Cassava stated that over 400 patients had enrolled in the trials. [28]
The publishing journals have issued expressions of concern for studies related to the pharmacology. [15] [18] [19]
Burns and Wang reported in 2008 that FLNA contains the high-affinity binding site of naloxone and naltrexone in preventing opioid tolerance and dependence, [15] and in 2020 that by disrupting that simufilam reduces the ultra-tight binding of amyloid beta 42 to the alpha-7 nicotinic receptor. [1] [18] Burns and Wang say that the FLNA linkage to the alpha 7 nicotinic receptor is critical to amyloid's toxic signaling through this receptor and that simufilam disrupts FLNA's linkage to this receptor to stop this toxic signaling. [18] They later demonstrated, by isoelectric focusing, that simufilam restores to normal an altered conformation of FLNA in Alzheimer's disease models or postmortem human brain tissue. [19] [20]
A 2020 study found simufilam improved epilepsy in a mouse model where FLNA was overexpressed. [29]
In June 2024, a grand jury indicted Wang on charges of falsifying data to obtain grants. [30]
As of July 2022, Cassava Sciences and papers published by Burns and Wang were under investigation by the U.S. Justice Department; Cassava denies any wrongdoing. [31] [10] Two papers were retracted by journals and expressions of concern were issued for other papers. [32] The U.S. Securities and Exchange Commission (SEC), the U.S. National Institutes of Health (NIH), and City University of New York (CUNY) were also investigating allegations of manipulated data. [10]
In October 2023, a leaked CUNY report indicated that they could obtain none of Wang's original data, which meant that they were unable to either prove or disprove allegations that the images were improperly manipulated; [7] [33] they paused the investigation a few weeks later over concerns about confidentiality and integrity of the process. [34]
Research papers demonstrating the mechanism of action of simufilam contained an error of units in methods (one instance of milligrams noted as micrograms) and erroneous duplication of images, but neither journal found evidence of data manipulation that was previously alleged. [35] [36] Two papers unrelated to Alzheimer's disease that reported FLNA binding by certain opioid antagonists and FLNA's role in opioid tolerance and dependence were retracted for "similarities in background pixels" in western blot images without evidence of data manipulation. [37] [38]
Lawrence Sterling Honig, professor of neurology at Columbia University Irving Medical Center, had remarked on Burns and Wang's claims: "But in fact, all the evidence seems to be from this [Wang's] lab." [6] Robert Howard, professor of psychiatry at the University College London, is concerned on the lack of placebo and small sample size and said that the research "at the very least is implausible". Thomas C. Südhof, Nobel laureate neuroscientist at Stanford University, also commented: "The overall conclusions with regard to Alzheimer's disease make no sense to me whatsoever... [The findings of Burns and Wang] are not in the mainstream of the field, and to me they seem implausible and contrived." [6]
Naloxone, the active ingredient in Narcan, is an opioid antagonist: a medication used to reverse or reduce the effects of opioids. Naloxone is commonly used to restore breathing after an opioid overdose. Effects begin within two minutes when given intravenously, five minutes when injected into a muscle, and ten minutes as a nasal spray. Naloxone blocks the effects of opioids for 30 to 90 minutes.
Naltrexone, sold under the brand name Revia among others, is a medication primarily used to manage alcohol use or opioid use disorder by reducing cravings and feelings of euphoria associated with substance use disorder. It has also been found effective in the treatment of other addictions and may be used for them off-label. An opioid-dependent person should not receive naltrexone before detoxification. It is taken by mouth or by injection into a muscle. Effects begin within 30 minutes, though a decreased desire for opioids may take a few weeks to occur. Side effects may include trouble sleeping, anxiety, nausea, and headaches. In those still on opioids, opioid withdrawal may occur. Use is not recommended in people with liver failure. It is unclear if use is safe during pregnancy. Naltrexone is an opioid antagonist and works by blocking the effects of opioids, including both opioid drugs as well as opioids naturally produced in the brain.
Ampakines or AMPAkines are a subgroup of AMPA receptor positive allosteric modulators with a benzamide or closely related chemical structure. They are also known as "CX compounds". Ampakines take their name from the AMPA receptor (AMPAR), a type of ionotropic glutamate receptor with which the ampakines interact and act as positive allosteric modulators (PAMs) of. Although all ampakines are AMPAR PAMs, not all AMPAR PAMs are ampakines.
CX717 is an ampakine compound created by Christopher Marrs and Gary Rogers in 1996 at Cortex Pharmaceuticals. It affects the neurotransmitter glutamate, with trials showing the drug improves cognitive functioning and memory.
Amyloid-beta precursor protein (APP) is an integral membrane protein expressed in many tissues and concentrated in the synapses of neurons. It functions as a cell surface receptor and has been implicated as a regulator of synapse formation, neural plasticity, antimicrobial activity, and iron export. It is coded for by the gene APP and regulated by substrate presentation. APP is best known as the precursor molecule whose proteolysis generates amyloid beta (Aβ), a polypeptide containing 37 to 49 amino acid residues, whose amyloid fibrillar form is the primary component of amyloid plaques found in the brains of Alzheimer's disease patients.
NMDA receptor antagonists are a class of drugs that work to antagonize, or inhibit the action of, the N-Methyl-D-aspartate receptor (NMDAR). They are commonly used as anesthetics for humans and animals; the state of anesthesia they induce is referred to as dissociative anesthesia.
Diprenorphine, also known as diprenorfin, is a non-selective, high-affinity, weak partial agonist of the μ- (MOR), κ- (KOR), and δ-opioid receptor (DOR) which is used in veterinary medicine as an opioid antagonist. It is used to reverse the effects of super-potent opioid analgesics such as etorphine and carfentanil that are used for tranquilizing large animals. The drug is not approved for use in humans.
Toll-like receptor 4 (TLR4), also designated as CD284, is a key activator of the innate immune response and plays a central role in the fight against bacterial infections. TLR4 is a transmembrane protein of approximately 95 kDa that is encoded by the TLR4 gene.
The sigma-2 receptor (σ2R) is a sigma receptor subtype that has attracted attention due to its involvement in diseases such as neurological diseases, neurodegenerative, neuro-ophthalmic and cancer. It is currently under investigation for its potential diagnostic and therapeutic uses.
Low density lipoprotein receptor-related protein 1 (LRP1), also known as alpha-2-macroglobulin receptor (A2MR), apolipoprotein E receptor (APOER) or cluster of differentiation 91 (CD91), is a protein forming a receptor found in the plasma membrane of cells involved in receptor-mediated endocytosis. In humans, the LRP1 protein is encoded by the LRP1 gene. LRP1 is also a key signalling protein and, thus, involved in various biological processes, such as lipoprotein metabolism and cell motility, and diseases, such as neurodegenerative diseases, atherosclerosis, and cancer.
Filamin A, alpha (FLNA) is a protein that in humans is encoded by the FLNA gene.
Homotaurine is a natural sulfonic acid found in seaweed. It is analogous to taurine, but with an extra carbon in its chain. It has GABAergic activity, apparently by mimicking GABA, which it resembles.
An opioid overdose is toxicity due to excessive consumption of opioids, such as morphine, codeine, heroin, fentanyl, tramadol, and methadone. This preventable pathology can be fatal if it leads to respiratory depression, a lethal condition that can cause hypoxia from slow and shallow breathing. Other symptoms include small pupils and unconsciousness; however, its onset can depend on the method of ingestion, the dosage and individual risk factors. Although there were over 110,000 deaths in 2017 due to opioids, individuals who survived also faced adverse complications, including permanent brain damage.
Lindsay H. Burns is an American neuroscientist and rower who won a silver medal at the 1996 Summer Olympics. She is a senior vice president of the pharmaceutical company Cassava Sciences and married to its CEO Remi Barbier.
(+)-Naloxone (dextro-naloxone) is a drug which is the opposite enantiomer of the opioid antagonist drug (−)-naloxone. Unlike (−)-naloxone, (+)-naloxone has no significant affinity for opioid receptors, but instead has been discovered to act as a selective antagonist of Toll-like receptor 4. This receptor is involved in immune system responses, and activation of TLR4 induces glial activation and release of inflammatory mediators such as TNF-α and Interleukin-1.
David S. Bredt is an American molecular neuroscientist.
A receptor modulator, or receptor ligand, is a general term for a substance, endogenous or exogenous, that binds to and regulates the activity of chemical receptors. They are ligands that can act on different parts of receptors and regulate activity in a positive, negative, or neutral direction with varying degrees of efficacy. Categories of these modulators include receptor agonists and receptor antagonists, as well as receptor partial agonists, inverse agonists, orthosteric modulators, and allosteric modulators, Examples of receptor modulators in modern medicine include CFTR modulators, selective androgen receptor modulators (SARMs), and muscarinic ACh receptor modulators.
Blarcamesine is an experimental drug developed by Anavex Life Sciences.
Sodium oligomannate is a mixture of oligosaccharides isolated from the marine algae Ecklonia kurome that is used in China as a treatment for Alzheimer's disease (AD).
Cassava Sciences is an American pharmaceutical company based in Austin, Texas. The company was founded in 1998 by chief executive officer and president Remi Barbier as Pain Therapeutics, Inc., changing its name in 2019.